391 related articles for article (PubMed ID: 18404673)
1. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Struthers A; Krum H; Williams GH
Clin Cardiol; 2008 Apr; 31(4):153-8. PubMed ID: 18404673
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
3. Eplerenone--a novel selective aldosterone blocker.
Zillich AJ; Carter BL
Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Karagiannis A; Athyros VG; Mikhailidis DP
Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701
[No Abstract] [Full Text] [Related]
5. The risks and benefits of aldosterone antagonists.
Sica DA
Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
[TBL] [Abstract][Full Text] [Related]
6. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
George J; Struthers AD
Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
9. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Barnes BJ; Howard PA
Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
[TBL] [Abstract][Full Text] [Related]
10. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.
Danjuma MI; Mukherjee I; Makaronidis J; Osula S
Curr Hypertens Rep; 2014 Feb; 16(2):414. PubMed ID: 24407447
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
12. Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist.
McManus F; McInnes GT; Connell JM
Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):44-52. PubMed ID: 18084345
[TBL] [Abstract][Full Text] [Related]
13. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
14. Review article: eplerenone: an underused medication?
Abuannadi M; O'Keefe JH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
[TBL] [Abstract][Full Text] [Related]
15. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
[No Abstract] [Full Text] [Related]
16. New treatment option for heart failure patients: eplerenone.
Southworth MR; Cavallari LH
J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
[TBL] [Abstract][Full Text] [Related]
17. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
[TBL] [Abstract][Full Text] [Related]
18. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
[TBL] [Abstract][Full Text] [Related]
19. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
Manolis AA; Manolis TA; Melita H; Manolis AS
Curr Hypertens Rep; 2019 Mar; 21(3):22. PubMed ID: 30826898
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]